What question did this study set out to answer?

The aim is to compare non-invasive markers for atrial cardiomyopathy and their association with arrhythmia recurrence post-ablation.

April 1, 2026Open Access

Head-to-head comparison of non-invasive markers of atrial cardiomyopathy and their association with arrhythmia recurrence after atrial fibrillation ablation

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Atrial fibrillation (n=200). Intervention: Amplified P-wave duration ≥ 150 ms vs. Amplified P-wave duration < 150 ms. Primary outcome: Relevant atrial cardiomyopathy (LA-LVS extent ≥ 20%) (OR 11.46, 95% CI 2.27-57.90, p=0.003).

Resultado clave

Amplified P-wave duration ≥ 150 ms was independently associated with relevant atrial cardiomyopathy (OR 11.46) and predicted arrhythmia recurrence (HR 2.01) in patients undergoing atrial fibrillation ablation.

Puntos clave

The aim is to compare non-invasive markers for atrial cardiomyopathy and their association with arrhythmia recurrence post-ablation.
Conducted in patients undergoing first-time atrial fibrillation ablation.
Evaluated PWD as a non-invasive marker.
Analyzed associations with left atrial volume and arrhythmia recurrence.
Amplified PWD was identified as the most reliable non-invasive marker of atrial cardiomyopathy.
It showed an independent association with invasively assessed left atrial volume and arrhythmia recurrence.
Highlighted the potential of advanced surface ECG analysis for clinical risk stratification.

Diseño del estudio

Tipo

Cohort (n=200)

Multicéntrico

PICO estructurado

Does amplified P-wave duration predict relevant atrial cardiomyopathy and arrhythmia recurrence in patients with symptomatic atrial fibrillation undergoing first-time ablation?

Población

200 patients with symptomatic atrial fibrillation undergoing first-time pulmonary vein isolation with electroanatomical mapping, median age 69, 70% male

Intervención

Non-invasive markers of atrial cardiomyopathy (specifically amplified P-wave duration)

Resultado

Comparison of non-invasive markers of atrial cardiomyopathy with invasively quantified left atrial low-voltage substrate (LA-LVS extent)surrogate

Amplified P-wave duration ≥ 150 ms is a robust non-invasive marker for identifying relevant atrial cardiomyopathy and predicting arrhythmia recurrence after first-time AF ablation.

Resultado numérico

Estimación del efecto: OR 11.46 (95% CI 2.27-57.90)

Tasa de eventos absoluta: 58.5% vs 8.8%

valor p: p=0.003

Limitaciones

Single-center, retrospective study design
Voltage thresholds and mapping techniques remain subject to methodological variability
Tissue proximity index during EAM was not used in all procedures
Arrhythmia recurrence was assessed using intermittent rhythm monitoring, which may underestimate asymptomatic recurrences
Inclusion required the availability of a baseline ECG recorded in sinus rhythm, potentially introducing selection bias

Resumen

In patients undergoing first-time AF ablation, amplified PWD emerged as the most robust non-invasive marker of AtCM, independently associated with invasively assessed LA-LVS and arrhythmia recurrence. Advanced surface ECG analysis may represent a practical and widely applicable tool for AtCM-associated risk stratification in routine clinical practice.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Dippel et al. (Mon,) conducted a cohort in Atrial fibrillation (n=200). Amplified P-wave duration ≥ 150 ms vs. Amplified P-wave duration < 150 ms was evaluated on Relevant atrial cardiomyopathy (LA-LVS extent ≥ 20%) (OR 11.46, 95% CI 2.27-57.90, p=0.003). Amplified P-wave duration ≥ 150 ms was independently associated with relevant atrial cardiomyopathy (OR 11.46) and predicted arrhythmia recurrence (HR 2.01) in patients undergoing atrial fibrillation ablation.

synapsesocial.com/papers/69ccb72e16edfba7beb89013 https://doi.org/https://doi.org/10.1007/s00392-026-02908-4

Me gusta

Guardar

Ver artículo completo